Literature DB >> 19101912

Graft fibrosis after pediatric liver transplantation: ten years of follow-up.

Rene Scheenstra1, Paul M G J Peeters, Henkjan J Verkade, Annette S H Gouw.   

Abstract

UNLABELLED: Previously we reported the presence of portal fibrosis in 31% (n = 84) of the grafts in protocol biopsies 1 year after pediatric liver transplantation (LTx). To assess the natural history of graft fibrosis after pediatric liver transplantation, we extended the analysis of graft histology in follow-up protocol biopsy specimens obtained 5 and 10 years after transplantation. We correlated histological results with clinical parameters at the time of LTx and during follow-up, to allow identification of risk factors for the development of fibrosis. From 1 year to 5 years after LTx, the prevalence of fibrosis increased from 31% to 65% (n = 66) but remained stable thereafter (at 10 years, 69%, n = 55). At 10 years after LTx, however, the percentage of patients with severe fibrosis had increased from 10% (at 5 years) to 29%. Of the 69% of children without fibrosis at 1 year post-transplantation, 64% (n = 39) had developed some degree of fibrosis at 10 years. Fibrosis was strongly related to transplant-related factors such as prolonged cold ischemia time, young age at the time of transplantation, high donor/recipient age ratio, and the use of partial grafts (P < 0.05). Fibrosis was not significantly related to rejection, chronic hepatitis, or the nature of the immunosuppressive therapy.
CONCLUSION: Biopsies after pediatric LTx show that most grafts developed fibrosis within 5 years. At 10 years after LTx, the graft fibrosis had progressed to severe fibrosis in at least 25% of the patients. Development of fibrosis, starting either before or after the first year post-LTx, was strongly related to transplant-related factors, indicating the importance of these factors to long-term graft prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19101912     DOI: 10.1002/hep.22686

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

1.  The risk factors of persistent thrombocytopenia and splenomegaly after liver transplantation.

Authors:  Toshiharu Matsuura; Makoto Hayashida; Isamu Saeki; Tomoaki Taguchi
Journal:  Pediatr Surg Int       Date:  2010-10       Impact factor: 1.827

Review 2.  What determines ageing of the transplanted liver?

Authors:  Russell Hodgson; Chris Christophi
Journal:  HPB (Oxford)       Date:  2014-09-28       Impact factor: 3.647

Review 3.  Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.

Authors:  Silvia Berardis; Prenali Dwisthi Sattwika; Mustapha Najimi; Etienne Marc Sokal
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

4.  Protocol liver biopsy is the only examination that can detect mid-term graft fibrosis after pediatric liver transplantation.

Authors:  Yukihiro Sanada; Koshi Matsumoto; Taizen Urahashi; Yoshiyuki Ihara; Taiichi Wakiya; Noriki Okada; Naoya Yamada; Yuta Hirata; Koichi Mizuta
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

5.  Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury.

Authors:  Yuan Liu; Tianfei Lu; Cheng Zhang; Jin Xu; Zhengze Xue; Ronald W Busuttil; Ning Xu; Qiang Xia; Jerzy W Kupiec-Weglinski; Haofeng Ji
Journal:  J Hepatol       Date:  2019-06-13       Impact factor: 25.083

6.  Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R.

Authors:  Sandy Feng; Anthony J Demetris; Katharine M Spain; Sai Kanaparthi; Bryna E Burrell; Udeme D Ekong; Estella M Alonso; Philip Rosenthal; Laurence A Turka; David Ikle; Nadia K Tchao
Journal:  Hepatology       Date:  2016-07-27       Impact factor: 17.425

7.  Evidence of Chronic Allograft Injury in Liver Biopsies From Long-term Pediatric Recipients of Liver Transplants.

Authors:  Sandy Feng; John C Bucuvalas; Anthony J Demetris; Bryna E Burrell; Katherine M Spain; Sai Kanaparthi; John C Magee; David Ikle; Andrew Lesniak; Juan J Lozano; Estella M Alonso; Robert A Bray; Nancy E Bridges; Edward Doo; Howard M Gebel; Nitika A Gupta; Ryan W Himes; Annette M Jackson; Steven J Lobritto; George V Mazariegos; Vicky L Ng; Elizabeth B Rand; Averell H Sherker; Shikha Sundaram; Yumirle P Turmelle; Alberto Sanchez-Fueyo
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

Review 8.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 9.  The SPLIT research agenda 2013.

Authors:  Estella M Alonso; Vicky L Ng; Ravinder Anand; Christopher D Anderson; Udeme D Ekong; Emily M Fredericks; Katryn N Furuya; Nitika A Gupta; Stacee M Lerret; Shikha Sundaram; Greg Tiao
Journal:  Pediatr Transplant       Date:  2013-05-30

10.  Production of Proinflammatory Cytokines by Monocytes in Liver-Transplanted Recipients with De Novo Autoimmune Hepatitis Is Enhanced and Induces TH1-like Regulatory T Cells.

Authors:  Adam S Arterbery; Awo Osafo-Addo; Yaron Avitzur; Maria Ciarleglio; Yanhong Deng; Steven J Lobritto; Mercedes Martinez; David A Hafler; Markus Kleinewietfeld; Udeme D Ekong
Journal:  J Immunol       Date:  2016-04-18       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.